Cannabis for dementia and Parkinson's — what the studies show

TL;DR

• Largest RCT (van der Elst 2021): no significant THC effect on dementia agitation.
• Earlier smaller studies more positive but methodologically weaker.
• In Parkinson's: hints of better sleep, no robust motor effect.
• Bottom line: evidence for dementia/Parkinson's is markedly weaker than for pain or nausea.

Dementia agitation: from hope to disappointment

In the 1990s a small case series on dronabinol in Alzheimer's patients with anorexia and agitation (Volicer 1997) generated optimism. Nabilone case series (Ahmed 2015) followed with a similarly positive picture. But the largest and methodologically strongest randomised crossover trial, published in 2021 (van der Elst, BMJ Open), using THC 1.5 mg three times daily, found no significant difference from placebo on neuropsychiatric symptoms. This result markedly tempers earlier positive reports and underscores the importance of methodologically strong studies.

Parkinson's: focus on non-motor symptoms

For Parkinson's, the most plausible benefit is sleep quality, pain and anxiety — not the cardinal motor symptoms (tremor, rigidity, bradykinesia), where studies mostly show absent or inconsistent effects. Patients should not view cannabis as a substitute for standard dopaminergic therapy, but at most as an adjunct for symptomatic relief.

The Swiss legal framework and prescription pathway

Since the amendment to the law in August 2022, access to medical cannabis in Switzerland has been significantly simplified for patients. Doctors can now prescribe corresponding preparations directly on a narcotics prescription, without the need to obtain a time-consuming exceptional authorisation from the Federal Office of Public Health (BAG). This change particularly relieves relatives of people affected by dementia and Parkinson's disease, who previously faced high bureaucratic hurdles. Prescriptions are issued within the scope of the treating specialists' therapeutic freedom, and they must carefully assess the indication.

However, coverage of costs by the compulsory health insurance is still not automatically regulated in Switzerland. Since medical cannabis is not standardly listed on the Specialties List, treating physicians must submit a justified request for cost coverage to the respective health insurance provider. The insurance company's medical consultant then reviews on a case-by-case basis whether the treatment is considered scientifically sufficiently justified. In practice, this requires detailed documentation of previous, unsuccessful standard therapies and the intended therapeutic goals.

• Direct prescription option by Swiss doctors since August 2022.
• Abolition of the previously mandatory exceptional authorisation by the Federal Office of Public Health (BAG).
• No automatic coverage of costs by the compulsory health insurance.
• Necessity of an individual application for cost coverage to the health insurance provider.

Interactions with Parkinson's and dementia medication

Elderly people with neurodegenerative diseases usually already take a multitude of medications, which massively increases the risk of adverse interactions. Cannabinoids such as THC and CBD are metabolized in the liver via the cytochrome P450 enzyme system. Since many standard therapeutics for Parkinson's, such as dopamine agonists, or anti-dementia drugs also use this metabolic pathway, mutual interactions can occur. In the worst-case scenario, this leads to unpredictable fluctuations in active substance concentrations in the blood, which either weakens the effect or increases toxicity.

The combination of cannabis with sedating medications or antihypertensives is particularly critical. The blood pressure-lowering effect of cannabinoids, when combined with Parkinson's medications that already lead to orthostatic hypotension, can intensify sudden feelings of dizziness when standing up. In addition, the depressant effect on the central nervous system can further restrict cognitive performance and increase the daytime sleepiness typical of Parkinson's. Close monitoring of all vital signs and regular blood count checks by the treating physicians are therefore indispensable throughout the entire duration of therapy.

• Breakdown of cannabinoids via the hepatic cytochrome P450 enzyme system.
• Risk of altered active substance levels of Parkinson's and dementia medications.
• Exacerbation of drops in blood pressure in combination with antihypertensives.
• Increased sedation and enhanced daytime sleepiness when co-administered with sedatives.

Practical dosage forms and dosing principles

For elderly patients with motor or cognitive impairments, choosing the right dosage form is of central importance. Inhalation using a vaporizer is ruled out in most cases of advanced dementia or severe Parkinson's tremor for practical and safety reasons. Instead, standardized oily drops, tinctures, or capsules have established themselves in medical practice. These oral or sublingual application forms enable precise dosing and are characterized by a delayed, but long-lasting and uniform course of action.

When it comes to dosing in the geriatric field, the medical principle of starting extremely low and increasing the dose very slowly applies without exception. Since the aging organism metabolizes cannabinoids more slowly and reacts more sensitively to psychoactive effects, therapeutic doses must be individually balanced. Relatives or nursing staff play a crucial role here, as they must supervise the daily administration and document changes in the patient's well-being. A structured diary helps to determine the minimum effective dose without disruptive side effects.

• Preference for oily drops, capsules, or sprays over inhalation.
• Precise dosing and long-lasting effects through oral administration.
• Consistent application of the therapeutic principle of slow dose titration.
• Important role of relatives and nursing staff in administration and documentation.

Risk assessment: risk of falls and cognitive side effects

The use of cannabinoid-based medicinal products in elderly people carries specific risks that must be carefully weighed against the potential benefits beforehand. Among the most common and dangerous side effects is an impairment of the sense of balance and motor coordination. Since Parkinson's patients already suffer from gait instability, consumption-related dizziness can significantly increase the risk of falls. Falls in old age often lead to severe bone fractures and permanent restriction of mobility, which is why extreme caution is advised here.

On a cognitive level, preparations containing THC in particular can lead to paradoxical reactions in people with dementia. Instead of the desired calming effect, acute states of confusion, disorientation, or even hallucinations may occur. These psychological side effects not only place a burden on those affected, but also significantly complicate daily care. In case of suspected overdose or severe adverse reactions, medical advice should be sought immediately or, in an emergency, the Swiss national emergency number for poisoning, Tox Info Suisse, should be contacted on 145.

• Increased risk of falls and injuries due to impaired balance.
• Possibility of paradoxical reactions such as acute confusion and disorientation in dementia.
• Risk of hallucinations and psychological changes if the THC dosage is too high.
• Tox Info Suisse (telephone 145) as an important point of contact in case of suspected overdose.

FAQ